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Abstract
In heroin fatalities the diagnosis of the cause of death, based only on chemical and toxicological data, may be
particularly difficult; a complete knowledge of the case history is fundamental. Thus, for each case analytical results
should be interpreted taking into account also autopsy findings, information from the scene and relevant medical
history. In fact wide variability is present in post-mortem blood concentration of morphine (MOR), the main
metabolite of heroin, which is usually the most important analytical result for the interpretation of the cause of death.
Recently, increasing interest has grown towards the role of the metabolites morphine-3-β-D-glucuronide (M3G) and
morphine-6-β-D-glucuronide (M6G) in mediating heroin effects. To this purpose SPE technique was employed to
extract MOR, M3G and M6G from autopsy blood samples. Subsequently a LC/MS-MS method for the determination
of these analytes was developed, using a gradient elution with a binary mobile phase, the analytes being revealed
by means of an ESI-QqQ Mass Spectrometer operating in positive ionization and MRM mode. After validation, the
method was applied to twenty-one blood specimens collected from cases of suspected acute narcotism which
previously underwent a Systematic Toxicological Analysis (STA) to highlight the presence of ethanol and of the main
drugs of abuse and/or their metabolites. The concentration ratios of MOR, M3G and M6G were investigated. The
influence of some risk factors, such as the contemporary use of alcohol, methadone or cocaine, was also studied.
Some important indications emerged: the ratio M3G/M6G, being quite constant, should be a valid reference value to
assess toxicity. Furthermore the value of M3G/M6G ratio detected in heroin addict, in this study, is lower than that
found in people who assume morphine for therapeutic purposes. This ratio could be of help to overcome the difficult
interpretation of chemical and toxicological data.
Keywords: Morphine; Morphine-3-β-D-glucuronide; Morphine-6-
β-D-glucuronide; Heroin fatalities; LC-MS; Autopsy blood
Introduction
Heroin fatal overdose is still a public health problem in most
countries, as described by the Annual Report of the OEDT [1]. Several
studies have therefore focused on this topic, but the exact mechanism
of fatal heroin overdose is still unclear. Typically death derives from
the administration of a dose beyond the current tolerance of the
person. This amount of drug induces respiratory depression till coma
and cardio-pulmonary arrest [2]. The cause of death is established by
the coroner, using the criteriology of the legal medicine, anamnestic
and circumstantial data. In heroin related deaths, chemical and
toxicological data are not as decisive as in the case of poisoning
determined by other drugs of abuse. Most deaths occur among
experienced users (around 35 years old, with 5-10 years of drug
addiction), who should be skilled in evaluating safe doses and have
high levels of tolerance, although this last aspect is hard to predict.
Nonetheless, these heroin addicts often suffer from pathologies, which
may influence drug metabolism and consequently increase toxicity [3].
The intake of a previously tolerated dose after loss/reduction of
tolerance (e.g. after heroin detoxification or after imprisonment) could
also be responsible for heroin intoxication. The contemporary use of
therapeutic or illicit drugs, especially methadone, benzodiazepines,
ethanol and cocaine, must also be considered. Several authors have
investigated the influence of these substances, in heroin fatalities [2-9].
Besides, heroin metabolism is quite complex. This drug can’t be
usually found in biological fluids because of its short half-life [2-4]
minutes after intravenous injection). In the body, heroin is indeed
rapidly hydrolyzed to 6-monoacetylmorphine (6-MAM), which in
turn is converted to morphine (MOR). This metabolite is conjugated
with glucuronic acid to mainly give morphine-3-β-D-glucuronide
(M3G) and morphine-6-β-D-glucuronide (M6G) [10].
The concentration of morphine in blood has frequently been
regarded as a measure of heroin action and toxicity. However, a
number of overdose fatalities show relatively low blood concentrations
of morphine, i.e. below or similar to those of living consumers or
intoxicated heroin users [3,7]. Some authors have studied the ratio of
“free” to “total” morphine, in order to correlate this value with the
time of death or the influence of other misused drugs [11-13]. “Free”
morphine stands for un-conjugated morphine, while “total” morphine
refers to the amount of morphine which is determined after
application of a hydrolysis step to the sample. In this way, morphine
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glucuronides, but also 6-MAM and other minor metabolites, are
converted to morphine and analyzed by GC/MS.
Class Case No AGE BAC (g/L) MOR M3G M6G M3G/M6G Relevant circumstances
I
1 45 0.1 358 1710 285 6.00 First injection? Family denies a history ofdrug dependence
2 22 n.p. 294 1148 317 3.62 led to the hospital; reported a double dose ofheroin
3 45 n.p. 166 250 60 4.17 Found dead in a toilet with a syringe nearby
4 44 0.3 254 266 92 2.89 Found dead at home with a syringe in the arm
5 31 n.p. 371 633 196 3.23 Found dead in a toilet with a syringe in thearm
6 34 0.4 60 788 165 4.78 Found dead in his car; injection sites atautopsy
7 27 n.p. 231 188 42 4.48 uk
8 28 n.p. 139 788 130 6.06 uk
9 30 n.p. 266 833 225 3.70 uk
10 40 n.p. 153 457 85 5.38 uk
II
11 39 0.7 187 427 92 4.64 Found dead at home with a syringe nearby
12 22 0.5 646 398 90 4.42 Found dead at home with suspected “brown-sugar”
13 39 0.7 649 2307 721 3.20 History of drug dependence; injection sites atautopsy
14 42 2.2 117 46 14 3.29 History of drug dependence; found dead athis home
15 35 1.3 152 322 88 3.66 Found dead in a toilet with a syringe nearby
16 32 1.0 156 97 50 1.94 Found dead with a syringe nearby
III
17 35 0.5 108 474 63 7.52 In treatment for heroin dependence
18 24 0.2 334 569 185 3.08 Found in his bed; no signs of injection; whitefoam and blood at the mouth and at the nose
19 30 0.1 515 2138 821 2.60 Found in his bed; no signs of injection; whitefoam and blood at the mouth and at the nose
20 45 0.6 1349 11 10 1.10 Found dead in a street with a syringe nearby
21 43 0.5 145 394 82 4.80 Found dead with a syringe nearby
Mean 316.68 678.29 181.57 4.03
± SD 289.21 646.04 213.25 1.47
Min 60 11 10 1.10
MAX 1349 2307 821 7.52
Table 1: Classification, age, gender and blood ethanol concentration of the twenty-one cases analyzed by LC/MS-MS (BAC=Blood Alcohol
Concentration; n.p.: not present, i.e. <0.5 g/L; M: male; uk: unknown). Concentrations (ng/mL) of morphine (MOR), morphine-3-β-D-
glucuronide (M3G), morphine-6-β-D-glucuronide (M6G) concentration ratio of the analytes (n.d.: not detected; /not calculated). Mean,
Standard Deviation (± SD) and range (min, MAX) of each analyte and of the ratios of analytes concentrations.
Indeed, this technique doesn’t allow the direct determination of
M3G and M6G. In the last years, however, increasing interest has
grown towards the role of these metabolites in mediating heroin or
morphine action [14-29].
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This paper describes a SPE extraction procedure and a validated
LC/MS-MS method for the simultaneous determination of heroin
metabolites in post-mortem blood samples. The development of
techniques able to simultaneously detect heroin metabolites is very
useful to try to elucidate the cause of death when dealing with
potential heroin related deaths.
The aim of the work was the investigation of the role of heroin
metabolites, so that the method was applied to blood specimens
belonging to cases of suspected heroin acute narcotism. Moreover, as
suggested by some authors [23-25], the concentration ratios of the
analytes were calculated and related to some risk factors, such as the
contemporary use of alcohol, methadone or cocaine. In particular the
ratio M3G/M6G was studied and compared to that found in people
assuming morphine for therapeutic purposes to understand if this
ratio could be an important reference to evaluate the changes which
occur in the glucuronidation mechanism in drug addicts.
Material and Methods
Reagents and standards
Morphine base (MOR) and morphine-D3 (MOR-D3) were supplied
by S.A.L.A.R.S. (Italy). Morphine-3-β-D-glucuronide (M3G),
morphine-6-β-D-glucuronide (M6G), morphine-3-β-D-glucuronide-
D3 (M3G-D3), morphine-6-β-D-glucuronide-D3 (M6G-D3) and 6-
monoacetylmorphine (6-MAM) were purchased from Cerilliant
(USA).
Water (18,2 mΩ/cm) was prepared by a Milli-Q System (Millipore,
France). Methanol was obtained from Sigma Aldrich (Germany) and
acetonitrile was supplied from Carlo Erba (Italy). Sodium tetraborate/
hydrochloric acid pH 9 buffer solution, formic acid and ammonium
formate were purchased from Fluka (Germany), while hexane and
ethyl acetate from Prolabo (Italy). All reagents were of analytical grade
and were stored as required by the manufacturer.
MOR, M3G, M6G and 6-MAM reference standards were used to
prepare calibration standard mixtures at 2000, 1000, 500, 250, 100
ng/mL in methanol. The internal standard mixture (ISM-D3) 1000
ng/mL in methanol was prepared by mixing MOR-D3, M3G-D3 and
M6G-D3 standards.
Post-mortem blood samples
Central blood samples (n=21) belonging to male subjects were
classified into three classes on the basis of Systematic Toxicological
Analysis (STA) results [11]. In detail the five classes and the
corresponding cases are:
I=Heroin: case No.1-10.
II=Heroin and ethanol (BAC ≥ 0.5 g/L): case No.11-16;
III=Heroin, methadone and ethanol (BAC ≥ 0.5 g/L): case No.17;
Heroin and cocaine: case No.18-19; Heroin, cocaine and ethanol (BAC
≥ 0.5 g/L): case No.20-21.
The available data concerning each case are given in Table 1.
LC/MS-MS analysis
The analyses were performed on a Varian LC-320 triple quadrupole
mass spectrometer, equipped with two Varian LC-212
chromatographic pumps and a Varian 410 tray cooled autosampler.
The system is managed by Varian Workstation software (Version
6.9.2).
Chromatographic separation was performed at 40°C on a Kinetex®
2.6 μm x 50 mm (Phenomenex) protected by a Security Guard column
C18 4 x 2.0 mm (Phenomenex). The mobile phase consisted of 3 mM
ammonium formate buffer pH=3.0 (phase A) and acetonitrile with
0.1% formic acid (phase B). Flow rate: 0.2 mL/min. Gradient: from 5%
phase B to 10% from 0.30 min to 5.0 min and then to 65.0% over the
next nine min, before returning to the initial conditions within 1 min
and equilibrating for 6 min. Total run time: 21 min. Injection volume:
10 μL. Manifold temperature: 42°C, housing temperature: 50°C.
Ionization was achieved using electrospray in the positive mode (ESI
+); needle voltage: +5000 V; shield voltage: +600 V; nebulizing gas
(N2) pressure: 0.276 KPa; drying gas (N2) pressure: 0.276 KPa; drying
gas (N2) temperature: 200°C. Multiple Reaction Monitoring (MRM)
mode was chosen for the detection, using Argon at a pressure of 267
Pa as CID gas.
Among the three analytes, M3G was first eluted, while the
separation between MOR and M6G was found to be particularly
challenging. MRM mode assured distinct identification, and moreover
a fairly good separation was achieved thanks to the application of a
slight gradient and a constant column temperature (Figure 1).
The MRM transitions selected for each analyte and its
corresponding deuterated internal standard (IS) are shown in Table 2.
Figure 1: Selected MRM chromatograms of morphine (MOR),
morphine-3-β-D-glucuronide (M3G) and morphine-6-β-D-
glucuronide (M6G) (R.T.=Retention Time).
Both the pseudotransition from pseudomolecular ion to
pseudomolecular ion and true transitions resulting from
fragmentation were taken into account. In the case of morphine the
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pseudotransition was used for quantification [14] because this
transition gave best results in terms of precision and linearity. In the
case of the glucuronides the transition corresponding to the true
fragmentation was used for quantitative determinations.
As regard as the detection of 6-MAM, MOR-D3 was used as IS; it
has to be noticed that in the experimental conditions adopted for M3G
and M6G, either chromatographic or extraction parameters, the large
ion suppression due to matrix effects (see Method validation section,
Figure 2) prevented us the contemporary detection of 6-MAM and
morphine metabolites.
Compound Q1 first mass Q3 first mass Capillary (V) Collision Energy (V)
MOR
286.3 286.3 70.9 6.0
286.3 201.2 70.9 15.0
M3G, M6G
462.2 462.2 32.9 5.0
462.2 286.1 32.9 27.5
MOR-D3
289.1 289.1 80.0 5.5
289.1 200.9 80.0 17.0
M3G-D3, M6G-D3
465.5 465.5 32.9 5.0
465.5 289.1 32.9 25.5
6-MAM
328.4 328.4 75.0 5.0
328.4 165.1 75.0 31.5
Table 2: MRM transitions of each analyte and corresponding IS.
Sample preparation
For each working day, the following samples were prepared and
analyzed: a “blank” solvent Working sample, a “blank” blood Working
sample; Working Standard samples (WSs) 10, 25, 50, 100 and 200 ng;
unknown Working samples.
Sample were composed of 0.5 mL of water or blood, 2.0 mL of
water, 2.0 mL of pH 9 buffer and 50 μL of ISM-D3.
0.5 mL of water, of “blank” blood and of each unknown blood
sample was transferred into a tube. 2 mL of water, 50 μL of ISM-D3
and 2.0 mL of pH 9 buffer solution were added. After vortex mixing
and centrifugation (3500 gm, 10 min), the supernatant was extracted
as described below.
The five WSs of MOR, M3G and M6G, were prepared by
transferring 100 μL of the calibration standard mixtures at 100, 250,
500, 1000 and 2000 ng/mL in five tubes and evaporating the solvent to
dryness under a stream of nitrogen at 40°C. 0.5 mL of “blank” blood
was then added to each tube and, after vortex mixing, the WSs were
handled as the unknown and “blank” specimens.
Solid-phase Extraction method
Samples were extracted using Bond Elut Certify® Varian cartridges,
conditioned with 2 mL of methanol and 2 mL of pH 9 buffer solutions
and not allowed to dry during this phase. After loading the sample,
keeping the flow at around 1 mL/min, the cartridge was washed with
4.0 mL of pH 9 buffer solutions, and subsequently dried under air flow
for around ten minutes.
Figure 2: Selected MRM chromatograms for 6-
monoacetylmorphine (6-MAM), in which it is evident the ion
suppression due to the matrix effect.
A final wash with 3.0 mL of a mixture hexane:ethyl acetate (8:2) was
applied and the cartridge was dried again under air flow for one
minute. The compounds of interest were finally eluted with 2 mL of
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methanol, the extract was dried under a nitrogen stream at 40°C and
the residue was reconstituted with 250 µL of mobile phase A and
analyzed. If the concentration of the analytes was above the range of
linearity, the samples were diluted, in order to obtain a concentration
following within the calibration range.
Statistical analysis
The mean of the concentration ratio M3G/M6G was compared to
the means of M3G/M6G of some reported by clinical trials using
Wilcoxon signed rank test.
Results
Method validation
Because of the complexity of “blank” matrices, a simplified
validation procedure and a higher variability and tolerance towards
the results were applied.
Specificity of the LC/MS-MS was evaluated by repeatedly extracting
and analyzing 0.5 mL of “blank” solvent and 0.5 mL of 10 “blank”
bloods from different sources spiked with 50 µL of the ISM-D3,
checking the presence of interfering peaks for each MRM at the R.T. of
the investigated compounds.
For the study of linearity, calibration curves were performed by
spiking 0.5 mL “blank” blood samples with five increasing
concentration levels (WSs 10, 25, 50, 100, 200 ng respectively) of
MOR, M3G and M6G. R2 values above 0.9940 were found for all the
analytes, indicating a good linearity of the method (Table 3).
The calculation of the concentration of the analytes and
repeatability were assessed determining the Response Ratio RR as
follows.
Compound Range (ng) Slope Intercept R2 LLOQ (ng) LOD (ng) RSD% REC% (± SD) %ME
MOR 10-200 0.045 0.029 0.9992 10 1 7.0 100.0 (± 7.0) 69.0
M3G 10-200 0.017 0.003 0.9995 10 1 11.0 100.0 (± 11.1) 40.4
M6G 10-200 0.015 0.055 0.9940 10 1 14.8 100.3 (± 14.3) 72.2
Table 3: Results of the validation study: range, slope, intercept and correlation coefficient (R2) of the linearity study; Lower Limit of Quantitation
(LLOQ); Limit of Detection (LOD); average percent Relative Standard Deviation (%RSD) and average percent Recovery (% REC) ± Standard
Deviation (SD) as a measure of the intermediate precision and of the accuracy of the method, respectively. Matrix effects (% M.E.) of WSs 50 ng
(n=5).
Five working standards solutions (Wws) were prepared and
analysed each day to determine RAstd defined as:
RAstd=Astd/AIS
Where Astd is the area of the peak of the quantifier MRM transition
of the standard solution; AIS is the area of the peak of the quantifier
MRM transition of the IS.
Then for each solution the response ratio RR was calculated as:
RR=RAstd / Cstd
Where Cstd is the concentration of the standard solution expressed
as total ng of analyte. This value was finally divided by the unknown
sample volume (0.5 mL) to get the concentration as ng/mL (of blood).
The RRmean was then determined as the mean of the five RR
obtained for the single standard solutions.
The concentration of analytes was determined applying the
following formula:
Cx=RAsample/RRmean
Where Cx=analyte concentration in the unknown specimen or the
standard concentration expressed as total ng of analyte. This value was
finally divided by the unknown sample volume (0.5 mL) to get the
concentration as ng/mL (of blood).
RAsample=ratio between the area of the peak of the quantifier MRM
transition of the analyte in the sample and the area of the peak of the
quantifier MRM transition of the IS; RRmean=mean response ratio
calculated from the analysis of five working standards.
Repeatability was evaluated by calculating the ± SD (Standard
Deviation) and the percent RSD (% Relative Standard Deviation) of
the Response Ratio (RR) of the five WSs prepared on three different
days for the study of linearity (Table 3).
For the study of the accuracy, each WSs of the linearity study was
quantified using the RRmediumTOT calculated for the study of
intermediate precision. The results (ngexp) were then compared to the
theoretical values (ngtheor) in order to calculate the corresponding
percent Recovery (% REC) of the method, by applying the following
formula: % REC=(ngexp/ngtheor) x100 (Table 3).
The LOD was set by analyzing a series of decreasing concentrations
of drug-fortified “blank” blood samples. On the basis of the results, the
LOD of the three analytes was set at 1 ng (Table 3). The LLOQ was
evaluated on the basis of the % RSD and % REC values of the lowest
WSs (10 ng) of the three regression lines calculated for the assessment
of linearity. Good results were obtained on each working day, so that
the LLOQ was set at 10 ng for all the molecules. A lower LLOQ could
be evaluated for morphine, but a 10 ng value was enough for the
purposes of our method (Table 3).
The following procedure [9] was applied to evaluate matrix effects.
Five WSs (50 ng) were prepared from “blank” blood and extracted by
SPE together with five “blank” blood samples, which were fortified
after SPE to become post-extraction WSs (50 ng). On the same day,
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five unextracted WSs (50 ng) were prepared in 3 mM ammonium
formate buffer.
Matrix effects for each analyte were expressed by a percent value,
calculated in the following way:
Matrix effect (%)=B/A x 100
where A is the average peak area of the unextracted standards and B
is the average peak area of the post-extraction WSbs.
As shown in Table 3 all the analytes, especially M3G, showed large
ion suppression (% ME). Nonetheless, the accuracy of the method was
not affected, as indicated by the validation study (% REC). In the case
of 6-MAM ion suppression was responsible for the fact that this
analyte, present in blood in low concentration, always resulted below
LOD and for this reason it was not possible to determine it.
Discussion
M3G is an inactive metabolite [17-18], the activity of M6G on µ-
opioid receptors has been demonstrated in a number of studies
[19-21], and this molecule is under investigation as therapeutic agent
for the treatment of post-operative pain [22-25]. From LC/MS-MS
results, the concentration ratio M3G/M6G was evaluated (Table 1).
As mentioned in the introduction, the interpretation of analytical
results is the most challenging task in post-mortem toxicology. As far
as the cause of death is concerned, a complete knowledge of the case
history is fundamental. Thus, for each case analytical results should be
interpreted taking into account also autopsy findings, information
from the scene and relevant medical history. Nonetheless, some
considerations are possible. A high variability in MOR blood
concentrations can be noticed, in accordance with literature. A wide
distribution of M3G and M6G concentrations is also present (Table 1).
If only the ten cases belonging to the class I are considered, this
variability is still present. This class includes cases in which only
heroin metabolites were found by the systematic toxicological analysis
(STA, 11), being therefore no evident risk factors present; for
classification, see also paragraph “Post-mortem blood samples”.
As suggested by some authors [24,25], the concentration ratio
M3G/M6G, was also evaluated (Table 1). Thus, the relationship
between two concentrations may be investigated. Looking at the ratios
of all the other cases, it can be noticed that variability is still present,
but within a narrower range (Table 1).
The relationship between analytical results and time of death was
also considered, as suggested by some authors [9,13,25].
Unfortunately, no great information about time of death was available.
Nonetheless, in case No.4 and No.5 people were found with a syringe
still in the arm, indicating that a quite immediate death had occurred.
The ratio of M3G to M6G is however quite close to the mean and to
the other ones in both cases, 2.89 and 3.23, respectively.
As described by several authors [3,4], heroin metabolism can be
affected by several factors, for example the contemporary use of other
psychoactive drugs. These substances may change blood
concentrations of heroin metabolites and/or contributing to
pharmacological and toxic effects. The twenty-one cases were
therefore divided into three classes according to the presence of other
drugs of abuse, as described in paragraph “Post-mortem blood
samples”. Mean values, ± SD and range were calculated for each class,
but no significant differences both in absolute concentrations and
ratios can be found, except for ethanol. As far as ethanol is concerned,
the cases were further classified into three groups according to BAC
(Blood Alcohol Concentration, g/L): the first group included case No.
1-10 (i.e. class I), where BAC was <0.5 g/L; in the second group, BAC
was between 0.5 and 1.0 and case No.11, 12 and 13 were included; the
third group was formed by cases No. 14, 15 and 16, which had a BAC
≥ 1.0 g/L. Cases No. 17-21 were not considered because also other
“risk factors” were present. We found that no significant differences
among the three groups were present.
In cases 18-21, STA revealed the contemporary use of cocaine; cases
No.18, 19 and 21 showed a ratio of M3G to M6G close to the mean
one, 3.08, 2.60 and 4.80 respectively. In case 20 a particularly low
M3G/M6G ratio was evidenced (1.10).
Finally, it must be underlined that a wide variability of the ratios of
morphine metabolites has been described also in the clinical field,
when morphine treatment is involved. In this regard, several authors
have demonstrated a lack of relationship between this value and long-
term or post-operative therapy outcomes [28,29]. In this work, a
significantly lower mean M3G/M6G (4.03 ± 1.47) compared to some
reported by clinical trials was found (p<0.0001) (Table 4). Other
authors confirm our data suggesting a mean M3G/M6G less than that
of morphine glucuronides detected in patient receiving morphine
therapy. (Table 5) [24] This finding is in accordance with other
published data [25] and seems to confirm that morphine
glucuronidation may change in drug addicts, as demonstrated by in
vitro results and outcomes from animals studies [29]. Certainly,
differences between morphine therapy and “street heroin” use, as well
as the overall health of patients and addicts, and also all the difficulties
of post-mortem toxicology, must be considered. Nonetheless, in
heroin fatalities M3G/M6G should be further investigated, beside
other concentrations and/or ratios, in order to study the role of some
risk factors, such as the contemporary use of ethanol and cocaine or
the loss of tolerance. To this purpose, a larger number of blood
samples will be analyzed, when available.
Drug Applicationroute Case n. M3G/M6G Reference
Morphine oral 34 6.5 [30]
Morphine oral 17 8.4 ± 3.3 [31]
Morphine intravenous 19 8.2 ± 3.3 [31]
Morphine oral 16 6.7 ± 1.0 [32]
Table 4: Morphine Glucuronides in serum or plasma of patients after
morphine therapy: mean ± standard deviation.
Drug Case n. M3G/M6G Reference
Heroin 21 3.30 ± 1.7 24
Heroin 21 4.03 ± 1.4 current study
Table 5: Concentration Ratio of M3G/M6G in blood of deceased
heroin addicts: mean ± standard deviation.
Conclusions
The optimized method for the determination of morphine and its
metabolites M3G and M6G in blood can lead to a better
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understanding of the mechanisms which are responsible for heroin
overdose fatalities. Form the preliminary analysis of the twenty-one
cases some important indications emerged which should be further
investigated: the ratio M3G/M6G, being quite constant, should be a
valid reference value to assess toxicity. Furthermore the value of
M3G/M6G ratio detected in heroin addict, in this study, is lower than
that found in people who assume morphine for therapeutic purposes.
The present study could be an important reference also to evaluate the
changes which occur in the glucuronidation mechanism in drug
addicts.
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